Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme

Completed · Phase 1/Phase 2

Conditions studied: Glioblastoma Multiforme

In brief

The purpose of this study is to evaluate the safety, tolerability and efficacy of VB-111 in patients with Relapsed Glioblastoma Multiforme.

Key facts

Study ID
NCT01260506
Run by
Vascular Biogenics Ltd. operating as VBL Therapeutics
People needed
75
Starts
2010-12-01
Expected to finish
2018-12-20
Last updated by the study team
2020-04-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.